Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease ...

In this case, one arm of the antibody binds to an infected cell carrying cytomegalovirus proteins. The other arm attaches directly to a T cell. The antibody acts as a physical bridge, pulling the T ...

Infection with a common virus may increase the risk of Type 2 diabetes in older adults, a new study from the Netherlands suggests. In the study, adults ages 85 and over who were infected with ...

CMV is the most common infectious cause of birth defects in the U.S.; there is no approved vaccine to prevent CMV CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage ...

Phase 2 study to confirm dose to be initiated in near term, with planned interim analysis through 3 months; Phase 3 study planning is underway CMV is the most common infectious cause of birth defects ...

Immunity against cytomegalovirus (CMV) is initiated after its recognition by Toll-like receptor 2 (TLR2). We assessed the association between a single-nucleotide polymorphism (SNP) that impairs TLR2 ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of ...